Table 2. Number (%) of patients with different castration levels of serum testosterone at 3, 6, and 9 months after treatment with LHRH agonists.
| Testosterone level | LHRH agonists | 3 months | 6 months | 9 months | p-valuea |
|---|---|---|---|---|---|
| Total | |||||
| 50 ng/dL | Goserelin (n=59) | 58 (98.3) | 59 (100.0) | 58 (98.3) | 0.768 |
| Triptorelin (n=44) | 44 (100.0) | 44 (100.0) | 44 (100.0) | ||
| Leuprolide (n=22) | 22 (100.0) | 22 (100.0) | 22 (100.0) | ||
| 20 ng/dL | Goserelin (n=59) | 55 (93.2) | 58 (98.3) | 55 (93.2) | 0.283 |
| Triptorelin (n=44) | 41 (93.2) | 44 (100.0) | 44 (100.0) | ||
| Leuprolide (n=22) | 20 (90.9) | 20 (90.9) | 21 (95.5) | ||
| 10 ng/dL | Goserelin (n=59) | 19 (32.2) | 22 (37.3) | 32 (54.2) | <0.001 |
| Triptorelin (n=44) | 33 (75.0) | 35 (79.5) | 41 (93.2) | ||
| Leuprolide (n=22) | 13 (59.1) | 12 (54.5) | 19 (86.4) | ||
| Patients with LHRH monotherapy | |||||
| 50 ng/dL | Goserelin (n=26) | 26 (100.0) | 26 (100.0) | 25 (96.2) | 0.897 |
| Triptorelin (n=19) | 19 (100.0) | 19 (100.0) | 19 (100.0) | ||
| Leuprolide (n=18) | 18 (100.0) | 18 (100.0) | 18 (100.0) | ||
| 20 ng/dL | Goserelin (n=26) | 25 (96.2) | 25 (96.2) | 24 (92.3) | 0.684 |
| Triptorelin (n=19) | 19 (100.0) | 19 (100.0) | 19 (100.0) | ||
| Leuprolide (n=18) | 17 (94.4) | 17 (94.4) | 18 (100.0) | ||
| 10 ng/dL | Goserelin (n=26) | 6 (23.1) | 5 (19.2) | 9 (34.6) | <0.001 |
| Triptorelin (n=19) | 15 (78.9) | 13 (68.4) | 17 (89.5) | ||
| Leuprolide (n=18) | 10 (55.6) | 9 (50.0) | 15 (83.3) |
LHRH, luteinizing hormone-releasing hormone.
a:p-value at 9 months.